Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

This study has been completed.
Sponsor:
Collaborator:
Astellas Pharma Inc
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01050062
First received: December 24, 2009
Last updated: April 4, 2014
Last verified: April 2014
  Purpose

The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.


Condition Intervention
Hypertension
Drug: Telmisartan 80mg
Drug: Telmisartan 40mg
Drug: Hydrochlorothiazide 12.5mg

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Post Marketing Surveillance on Long Drug Use of Micombi Combination Tablets in Patients With Hypertension

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Incidence of Adverse Events (AEs) [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    The number of patient with any AEs, patients with drug-related AEs


Secondary Outcome Measures:
  • Systolic Blood Pressure (SBP) [ Time Frame: Week 0 and Week 52 ] [ Designated as safety issue: No ]
    SBP is observed at Week 0 and Week 52. The change of SBP from Week 0 to Week 52 is calculated.

  • Diastolic Blood Pressure (DBP) [ Time Frame: Week 0 and Week 52 ] [ Designated as safety issue: No ]
    DBP is observed at Week 0 and Week 52. The change of DBP from Week 0 to Week 52 is calculated.

  • Target Blood Pressure Achievement Rate [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    The proportion of the patients with target blood pressure in 52 weeks administrative period. Target blood pressure is defined as 'Guidelines for the management of hypertension (JSH2009)': less than 140/90 (SBP/DBP) mmHg for >= 65 years old or cerebrovascular disorder patient; less than 130/80 in diabetes, chronic kidney disease or myocardial infarction patient; less than 130/85 mmHg for others patient.

  • Blood Pressure Normalised Rate [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    The proportion of the patients with normalized blood pressure in 52 weeks on administrative period. Normalized blood pressure is defined less than 140/90 (SBP/DBP) mmHg according to JSH2009


Enrollment: 1452
Study Start Date: January 2010
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Micombi® Combination Tablet AP Drug: Telmisartan 40mg
Combination tablet
Drug: Hydrochlorothiazide 12.5mg
Combination tablet
Micombi® Combination Tablet BP Drug: Telmisartan 80mg
Combination tablet
Drug: Hydrochlorothiazide 12.5mg
Combination tablet

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

1000

Criteria

Inclusion criteria:

Hypertensive patients who have never taken Micombi Tablets.

Exclusion criteria:

None

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01050062

  Hide Study Locations
Locations
Japan
Boehringer Ingelheim Investigational Site 111
Ageo, Japan
Boehringer Ingelheim Investigational Site 209
Aisho-cho, Japan
Boehringer Ingelheim Investigational Site 22
Aizubange-machi, Japan
Boehringer Ingelheim Investigational Site 234
Akashi, Japan
Boehringer Ingelheim Investigational Site 78
Akiruno, Japan
Boehringer Ingelheim Investigational Site 79
Akishima, Japan
Boehringer Ingelheim Investigational Site 235
Ako, Japan
Boehringer Ingelheim Investigational Site 288
Akune, Japan
Boehringer Ingelheim Investigational Site 236
Amagasaki, Japan
Boehringer Ingelheim Investigational Site 237
Amagasaki, Japan
Boehringer Ingelheim Investigational Site 280
Anan, Japan
Boehringer Ingelheim Investigational Site 160
Anjo, Japan
Boehringer Ingelheim Investigational Site 1
Asahikawa, Japan
Boehringer Ingelheim Investigational Site 51
Ashikaga, Japan
Boehringer Ingelheim Investigational Site 140
Atsugi, Japan
Boehringer Ingelheim Investigational Site 58
Azumino, Japan
Boehringer Ingelheim Investigational Site 138
Chiba, Japan
Boehringer Ingelheim Investigational Site 128
Chiba, Japan
Boehringer Ingelheim Investigational Site 141
Chigasaki, Japan
Boehringer Ingelheim Investigational Site 299
Chikujo-machi, Japan
Boehringer Ingelheim Investigational Site 44
Chikusei, Japan
Boehringer Ingelheim Investigational Site 80
Chofu, Japan
Boehringer Ingelheim Investigational Site 311
Ebino, Japan
Boehringer Ingelheim Investigational Site 257
Fuchu, Japan
Boehringer Ingelheim Investigational Site 71
Fuefuki, Japan
Boehringer Ingelheim Investigational Site 179
Fujieda, Japan
Boehringer Ingelheim Investigational Site 211
Fujiidera, Japan
Boehringer Ingelheim Investigational Site 112
Fukaya, Japan
Boehringer Ingelheim Investigational Site 206
Fukui, Japan
Boehringer Ingelheim Investigational Site 303
Fukuoka, Japan
Boehringer Ingelheim Investigational Site 302
Fukuoka, Japan
Boehringer Ingelheim Investigational Site 301
Fukuoka, Japan
Boehringer Ingelheim Investigational Site 300
Fukuoka, Japan
Boehringer Ingelheim Investigational Site 180
Fukuroi, Japan
Boehringer Ingelheim Investigational Site 23
Fukushima, Japan
Boehringer Ingelheim Investigational Site 258
Fukuyama, Japan
Boehringer Ingelheim Investigational Site 129
Funabashi, Japan
Boehringer Ingelheim Investigational Site 175
Gifu, Japan
Boehringer Ingelheim Investigational Site 174
Gifu, Japan
Boehringer Ingelheim Investigational Site 42
Gonohe-machi, Japan
Boehringer Ingelheim Investigational Site 113
Gyoda, Japan
Boehringer Ingelheim Investigational Site 212
Habikino, Japan
Boehringer Ingelheim Investigational Site 82
Hachioji, Japan
Boehringer Ingelheim Investigational Site 81
Hachioji, Japan
Boehringer Ingelheim Investigational Site 193
Hakusan, Japan
Boehringer Ingelheim Investigational Site 181
Hamamatsu, Japan
Boehringer Ingelheim Investigational Site 247
Hashimoto, Japan
Boehringer Ingelheim Investigational Site 142
Hatano, Japan
Boehringer Ingelheim Investigational Site 259
Hatsukaichi, Japan
Boehringer Ingelheim Investigational Site 276
Higashikagawa, Japan
Boehringer Ingelheim Investigational Site 83
Higashikurume, Japan
Boehringer Ingelheim Investigational Site 114
Higashimatsuyama, Japan
Boehringer Ingelheim Investigational Site 213
Higashiosaka, Japan
Boehringer Ingelheim Investigational Site 84
Hino, Japan
Boehringer Ingelheim Investigational Site 43
Hirosaki, Japan
Boehringer Ingelheim Investigational Site 263
Hiroshima, Japan
Boehringer Ingelheim Investigational Site 261
Hiroshima, Japan
Boehringer Ingelheim Investigational Site 260
Hiroshima, Japan
Boehringer Ingelheim Investigational Site 262
Hiroshima, Japan
Boehringer Ingelheim Investigational Site 45
Hitachinaka, Japan
Boehringer Ingelheim Investigational Site 266
Hofu, Japan
Boehringer Ingelheim Investigational Site 72
Hokuto, Japan
Boehringer Ingelheim Investigational Site 249
Ibara, Japan
Boehringer Ingelheim Investigational Site 214
Ibaraki, Japan
Boehringer Ingelheim Investigational Site 215
Ibaraki, Japan
Boehringer Ingelheim Investigational Site 130
Ichikawa, Japan
Boehringer Ingelheim Investigational Site 161
Ichinomiya, Japan
Boehringer Ingelheim Investigational Site 19
Ichinoseki, Japan
Boehringer Ingelheim Investigational Site 18
Ichinoseki, Japan
Boehringer Ingelheim Investigational Site 59
Ina, Japan
Boehringer Ingelheim Investigational Site 289
Isa, Japan
Boehringer Ingelheim Investigational Site 187
Ise, Japan
Boehringer Ingelheim Investigational Site 74
Isesaki, Japan
Boehringer Ingelheim Investigational Site 182
Ito, Japan
Boehringer Ingelheim Investigational Site 52
Iwafune-machi, Japan
Boehringer Ingelheim Investigational Site 24
Iwaki, Japan
Boehringer Ingelheim Investigational Site 162
Iwakura, Japan
Boehringer Ingelheim Investigational Site 216
Izumisano, Japan
Boehringer Ingelheim Investigational Site 194
Kaga, Japan
Boehringer Ingelheim Investigational Site 290
Kagoshima, Japan
Boehringer Ingelheim Investigational Site 73
Kai, Japan
Boehringer Ingelheim Investigational Site 195
Kanazawa, Japan
Boehringer Ingelheim Investigational Site 53
Kanuma, Japan
Boehringer Ingelheim Investigational Site 163
Kariya, Japan
Boehringer Ingelheim Investigational Site 238
Kasai, Japan
Boehringer Ingelheim Investigational Site 164
Kasugai, Japan
Boehringer Ingelheim Investigational Site 115
Kasukabe, Japan
Boehringer Ingelheim Investigational Site 217
Kawachinagano, Japan
Boehringer Ingelheim Investigational Site 116
Kawaguchi, Japan
Boehringer Ingelheim Investigational Site 117
Kawaguchi, Japan
Boehringer Ingelheim Investigational Site 231
Kawai-cho, Japan
Boehringer Ingelheim Investigational Site 145
Kawasaki, Japan
Boehringer Ingelheim Investigational Site 144
Kawasaki, Japan
Boehringer Ingelheim Investigational Site 143
Kawasaki, Japan
Boehringer Ingelheim Investigational Site 296
Kawatana-cho, Japan
Boehringer Ingelheim Investigational Site 40
Kazuno, Japan
Boehringer Ingelheim Investigational Site 29
Kesennuma, Japan
Boehringer Ingelheim Investigational Site 131
Kisarazu, Japan
Boehringer Ingelheim Investigational Site 2
Kitahiroshima, Japan
Boehringer Ingelheim Investigational Site 305
Kitakyushu, Japan
Boehringer Ingelheim Investigational Site 304
Kitakyushu, Japan
Boehringer Ingelheim Investigational Site 306
Kitakyusyu, Japan
Boehringer Ingelheim Investigational Site 239
Kobe, Japan
Boehringer Ingelheim Investigational Site 240
Kobe, Japan
Boehringer Ingelheim Investigational Site 242
Kobe, Japan
Boehringer Ingelheim Investigational Site 241
Kobe, Japan
Boehringer Ingelheim Investigational Site 25
Koriyama, Japan
Boehringer Ingelheim Investigational Site 118
Koshigaya, Japan
Boehringer Ingelheim Investigational Site 277
Kotohira, Japan
Boehringer Ingelheim Investigational Site 119
Kumagaya, Japan
Boehringer Ingelheim Investigational Site 291
Kumamoto, Japan
Boehringer Ingelheim Investigational Site 292
Kumamoto, Japan
Boehringer Ingelheim Investigational Site 284
Kunisaki, Japan
Boehringer Ingelheim Investigational Site 250
Kurashiki, Japan
Boehringer Ingelheim Investigational Site 264
Kure, Japan
Boehringer Ingelheim Investigational Site 265
Kure, Japan
Boehringer Ingelheim Investigational Site 285
Kusu-machi, Japan
Boehringer Ingelheim Investigational Site 200
Kyoto, Japan
Boehringer Ingelheim Investigational Site 199
Kyoto, Japan
Boehringer Ingelheim Investigational Site 198
Kyoto, Japan
Boehringer Ingelheim Investigational Site 197
Kyoto, Japan
Boehringer Ingelheim Investigational Site 85
Machida, Japan
Boehringer Ingelheim Investigational Site 307
Maebaru, Japan
Boehringer Ingelheim Investigational Site 146
Matsuda-machi, Japan
Boehringer Ingelheim Investigational Site 132
Matsudo, Japan
Boehringer Ingelheim Investigational Site 60
Matsumoto, Japan
Boehringer Ingelheim Investigational Site 61
Matsumoto, Japan
Boehringer Ingelheim Investigational Site 272
Matsuyama, Japan
Boehringer Ingelheim Investigational Site 273
Matsuyama, Japan
Boehringer Ingelheim Investigational Site 188
Matsuzaka, Japan
Boehringer Ingelheim Investigational Site 293
Minamata, Japan
Boehringer Ingelheim Investigational Site 30
Minamisanriku-cho, Japan
Boehringer Ingelheim Investigational Site 218
Minoo, Japan
Boehringer Ingelheim Investigational Site 46
Mito, Japan
Boehringer Ingelheim Investigational Site 312
Miyazaki, Japan
Boehringer Ingelheim Investigational Site 133
Mobara, Japan
Boehringer Ingelheim Investigational Site 20
Morioka, Japan
Boehringer Ingelheim Investigational Site 26
Motomiya, Japan
Boehringer Ingelheim Investigational Site 3
Mukawa-cho, Japan
Boehringer Ingelheim Investigational Site 86
Musashino, Japan
Boehringer Ingelheim Investigational Site 62
Nagano, Japan
Boehringer Ingelheim Investigational Site 63
Nagano, Japan
Boehringer Ingelheim Investigational Site 297
Nagasaki, Japan
Boehringer Ingelheim Investigational Site 192
Nagoya, Japan
Boehringer Ingelheim Investigational Site 166
Nagoya, Japan
Boehringer Ingelheim Investigational Site 167
Nagoya, Japan
Boehringer Ingelheim Investigational Site 168
Nagoya, Japan
Boehringer Ingelheim Investigational Site 165
Nagoya, Japan
Boehringer Ingelheim Investigational Site 314
Naha, Japan
Boehringer Ingelheim Investigational Site 41
Nakadori, Japan
Boehringer Ingelheim Investigational Site 54
Nakagawa-machi, Japan
Boehringer Ingelheim Investigational Site 176
Nakatsugawa, Japan
Boehringer Ingelheim Investigational Site 196
Nanao, Japan
Boehringer Ingelheim Investigational Site 278
Nankoku, Japan
Boehringer Ingelheim Investigational Site 232
Nara, Japan
Boehringer Ingelheim Investigational Site 31
Natori, Japan
Boehringer Ingelheim Investigational Site 4
Nayoro, Japan
Boehringer Ingelheim Investigational Site 313
Nichinan, Japan
Boehringer Ingelheim Investigational Site 66
Niigata, Japan
Boehringer Ingelheim Investigational Site 65
Niigata, Japan
Boehringer Ingelheim Investigational Site 147
Ninomiya-machi, Japan
Boehringer Ingelheim Investigational Site 243
Nishinomiya, Japan
Boehringer Ingelheim Investigational Site 244
Nishinomiya, Japan
Boehringer Ingelheim Investigational Site 169
Nishio, Japan
Boehringer Ingelheim Investigational Site 87
Nishitokyo, Japan
Boehringer Ingelheim Investigational Site 5
Obihiro, Japan
Boehringer Ingelheim Investigational Site 255
Oda, Japan
Boehringer Ingelheim Investigational Site 189
Odai-cho, Japan
Boehringer Ingelheim Investigational Site 16
Odate, Japan
Boehringer Ingelheim Investigational Site 148
Odawara, Japan
Boehringer Ingelheim Investigational Site 294
Ogi, Japan
Boehringer Ingelheim Investigational Site 286
Oita, Japan
Boehringer Ingelheim Investigational Site 287
Oita, Japan
Boehringer Ingelheim Investigational Site 252
Okayama, Japan
Boehringer Ingelheim Investigational Site 253
Okayama, Japan
Boehringer Ingelheim Investigational Site 251
Okayama, Japan
Boehringer Ingelheim Investigational Site 308
Omuta, Japan
Boehringer Ingelheim Investigational Site 309
Omuta, Japan
Boehringer Ingelheim Investigational Site 226
Osaka, Japan
Boehringer Ingelheim Investigational Site 220
Osaka, Japan
Boehringer Ingelheim Investigational Site 221
Osaka, Japan
Boehringer Ingelheim Investigational Site 222
Osaka, Japan
Boehringer Ingelheim Investigational Site 223
Osaka, Japan
Boehringer Ingelheim Investigational Site 224
Osaka, Japan
Boehringer Ingelheim Investigational Site 225
Osaka, Japan
Boehringer Ingelheim Investigational Site 219
Osaka, Japan
Boehringer Ingelheim Investigational Site 21
Oshu, Japan
Boehringer Ingelheim Investigational Site 6
Otaru, Japan
Boehringer Ingelheim Investigational Site 210
Otsu, Japan
Boehringer Ingelheim Investigational Site 75
Oura-machi, Japan
Boehringer Ingelheim Investigational Site 55
Oyama, Japan
Boehringer Ingelheim Investigational Site 67
Sado, Japan
Boehringer Ingelheim Investigational Site 150
Sagamihara, Japan
Boehringer Ingelheim Investigational Site 149
Sagamihara, Japan
Boehringer Ingelheim Investigational Site 274
Saijo, Japan
Boehringer Ingelheim Investigational Site 120
Saitama, Japan
Boehringer Ingelheim Investigational Site 121
Saitama, Japan
Boehringer Ingelheim Investigational Site 122
Saitama, Japan
Boehringer Ingelheim Investigational Site 229
Sakai, Japan
Boehringer Ingelheim Investigational Site 228
Sakai, Japan
Boehringer Ingelheim Investigational Site 227
Sakai, Japan
Boehringer Ingelheim Investigational Site 39
Sakata, Japan
Boehringer Ingelheim Investigational Site 134
Sakura, Japan
Boehringer Ingelheim Investigational Site 68
Sanjo, Japan
Boehringer Ingelheim Investigational Site 135
Sanmu, Japan
Boehringer Ingelheim Investigational Site 268
Sanyoonoda, Japan
Boehringer Ingelheim Investigational Site 267
Sanyoonoda, Japan
Boehringer Ingelheim Investigational Site 8
Sapporo, Japan
Boehringer Ingelheim Investigational Site 7
Sapporo, Japan
Boehringer Ingelheim Investigational Site 11
Sapporo, Japan
Boehringer Ingelheim Investigational Site 10
Sapporo, Japan
Boehringer Ingelheim Investigational Site 12
Sapporo, Japan
Boehringer Ingelheim Investigational Site 9
Sapporo, Japan
Boehringer Ingelheim Investigational Site 298
Sasebo, Japan
Boehringer Ingelheim Investigational Site 123
Satte, Japan
Boehringer Ingelheim Investigational Site 124
Sayama, Japan
Boehringer Ingelheim Investigational Site 33
Sendai, Japan
Boehringer Ingelheim Investigational Site 37
Sendai, Japan
Boehringer Ingelheim Investigational Site 36
Sendai, Japan
Boehringer Ingelheim Investigational Site 35
Sendai, Japan
Boehringer Ingelheim Investigational Site 32
Sendai, Japan
Boehringer Ingelheim Investigational Site 34
Sendai, Japan
Boehringer Ingelheim Investigational Site 69
Shibata, Japan
Boehringer Ingelheim Investigational Site 13
Shibetsu, Japan
Boehringer Ingelheim Investigational Site 125
Shiki, Japan
Boehringer Ingelheim Investigational Site 279
Shimanto, Japan
Boehringer Ingelheim Investigational Site 310
Shime-machi, Japan
Boehringer Ingelheim Investigational Site 183
Shimoda, Japan
Boehringer Ingelheim Investigational Site 248
Shingu, Japan
Boehringer Ingelheim Investigational Site 38
Shiraishi, Japan
Boehringer Ingelheim Investigational Site 136
Shiroi, Japan
Boehringer Ingelheim Investigational Site 184
Shizuoka, Japan
Boehringer Ingelheim Investigational Site 185
Shizuoka, Japan
Boehringer Ingelheim Investigational Site 269
Shunan, Japan
Boehringer Ingelheim Investigational Site 126
Soka, Japan
Boehringer Ingelheim Investigational Site 27
Sukagawa, Japan
Boehringer Ingelheim Investigational Site 190
Suzuka, Japan
Boehringer Ingelheim Investigational Site 88
Tachikawa, Japan
Boehringer Ingelheim Investigational Site 203
Takaoka, Japan
Boehringer Ingelheim Investigational Site 204
Takaoka, Japan
Boehringer Ingelheim Investigational Site 245
Takarazuka, Japan
Boehringer Ingelheim Investigational Site 77
Takasaki, Japan
Boehringer Ingelheim Investigational Site 76
Takasaki, Japan
Boehringer Ingelheim Investigational Site 177
Takayama, Japan
Boehringer Ingelheim Investigational Site 246
Tatsuno, Japan
Boehringer Ingelheim Investigational Site 47
Tokai-mura, Japan
Boehringer Ingelheim Investigational Site 70
Tokamachi, Japan
Boehringer Ingelheim Investigational Site 170
Tokoname, Japan
Boehringer Ingelheim Investigational Site 127
Tokorozawa, Japan
Boehringer Ingelheim Investigational Site 281
Tokushima, Japan
Boehringer Ingelheim Investigational Site 282
Tokushima, Japan
Boehringer Ingelheim Investigational Site 89
Tokyo Adachi-ku, Japan
Boehringer Ingelheim Investigational Site 90
Tokyo Adachi-ku, Japan
Boehringer Ingelheim Investigational Site 102
Tokyo Bunkyo-ku, Japan
Boehringer Ingelheim Investigational Site 92
Tokyo Chiyoda-ku, Japan
Boehringer Ingelheim Investigational Site 91
Tokyo Chiyoda-ku, Japan
Boehringer Ingelheim Investigational Site 93
Tokyo Kita-ku, Japan
Boehringer Ingelheim Investigational Site 94
Tokyo Koto-ku, Japan
Boehringer Ingelheim Investigational Site 96
Tokyo Meguro-ku, Japan
Boehringer Ingelheim Investigational Site 95
Tokyo Meguro-ku, Japan
Boehringer Ingelheim Investigational Site 97
Tokyo Nerima-ku, Japan
Boehringer Ingelheim Investigational Site 99
Tokyo Ota-ku, Japan
Boehringer Ingelheim Investigational Site 98
Tokyo Ota-ku, Japan
Boehringer Ingelheim Investigational Site 101
Tokyo Setagaya-ku, Japan
Boehringer Ingelheim Investigational Site 100
Tokyo Setagaya-ku, Japan
Boehringer Ingelheim Investigational Site 103
Tokyo Shibuya-ku, Japan
Boehringer Ingelheim Investigational Site 106
Tokyo Shinagawa-ku, Japan
Boehringer Ingelheim Investigational Site 105
Tokyo Shinagawa-ku, Japan
Boehringer Ingelheim Investigational Site 104
Tokyo Shinagawa-ku, Japan
Boehringer Ingelheim Investigational Site 107
Tokyo Shinjuku-ku, Japan
Boehringer Ingelheim Investigational Site 108
Tokyo Suginami-ku, Japan
Boehringer Ingelheim Investigational Site 109
Tokyo Sumida-ku, Japan
Boehringer Ingelheim Investigational Site 110
Tokyo Toshima-ku, Japan
Boehringer Ingelheim Investigational Site 14
Tomakomai, Japan
Boehringer Ingelheim Investigational Site 28
Tomioka-machi, Japan
Boehringer Ingelheim Investigational Site 295
Tosu, Japan
Boehringer Ingelheim Investigational Site 270
Tottori, Japan
Boehringer Ingelheim Investigational Site 15
Toyako-machi, Japan
Boehringer Ingelheim Investigational Site 205
Toyama, Japan
Boehringer Ingelheim Investigational Site 171
Toyohashi, Japan
Boehringer Ingelheim Investigational Site 172
Toyokawa, Japan
Boehringer Ingelheim Investigational Site 230
Toyonaka, Japan
Boehringer Ingelheim Investigational Site 173
Toyota, Japan
Boehringer Ingelheim Investigational Site 49
Tsuchiura, Japan
Boehringer Ingelheim Investigational Site 207
Tsuruga, Japan
Boehringer Ingelheim Investigational Site 208
Tsuruga, Japan
Boehringer Ingelheim Investigational Site 283
Tsurugi-cho, Japan
Boehringer Ingelheim Investigational Site 254
Tsuyama, Japan
Boehringer Ingelheim Investigational Site 64
Ueda, Japan
Boehringer Ingelheim Investigational Site 201
Uji, Japan
Boehringer Ingelheim Investigational Site 48
Ushiku, Japan
Boehringer Ingelheim Investigational Site 57
Utsunomiya, Japan
Boehringer Ingelheim Investigational Site 56
Utsunomiya, Japan
Boehringer Ingelheim Investigational Site 275
Uwajima, Japan
Boehringer Ingelheim Investigational Site 137
Yachimata, Japan
Boehringer Ingelheim Investigational Site 186
Yaizu, Japan
Boehringer Ingelheim Investigational Site 178
Yamagata, Japan
Boehringer Ingelheim Investigational Site 151
Yamato, Japan
Boehringer Ingelheim Investigational Site 233
Yamatokooriyama, Japan
Boehringer Ingelheim Investigational Site 191
Yokkaichi, Japan
Boehringer Ingelheim Investigational Site 157
Yokohama, Japan
Boehringer Ingelheim Investigational Site 156
Yokohama, Japan
Boehringer Ingelheim Investigational Site 154
Yokohama, Japan
Boehringer Ingelheim Investigational Site 158
Yokohama, Japan
Boehringer Ingelheim Investigational Site 155
Yokohama, Japan
Boehringer Ingelheim Investigational Site 153
Yokohama, Japan
Boehringer Ingelheim Investigational Site 152
Yokohama, Japan
Boehringer Ingelheim Investigational Site 159
Yokosuka, Japan
Boehringer Ingelheim Investigational Site 271
Yonago, Japan
Boehringer Ingelheim Investigational Site 202
Yosano-cho, Japan
Boehringer Ingelheim Investigational Site 256
Yoshika-cho, Japan
Boehringer Ingelheim Investigational Site 139
Yotsukaido, Japan
Boehringer Ingelheim Investigational Site 50
Yuki, Japan
Boehringer Ingelheim Investigational Site 17
Yurihonjo, Japan
Sponsors and Collaborators
Boehringer Ingelheim
Astellas Pharma Inc
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01050062     History of Changes
Other Study ID Numbers: 502.542
Study First Received: December 24, 2009
Results First Received: December 18, 2012
Last Updated: April 4, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases
Hydrochlorothiazide
Telmisartan
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents
Diuretics
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on October 20, 2014